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Abstract Our previous studies established cardio-pro-
tective effects of furnidipine and its active metabolites
called M-2 and M-3. The aim of current research was to
compare the effects of single oral pretreatment with
20 mg kg-1 of M-2 and M-3 on mortality, different forms
of arrhythmias, blood pressures parameters and ST-seg-
ment changes during occlusion (for 90 min) and reperfu-
sion in the model of myocardial infarction in rats evoked
by left anterior descending coronary artery occlusion.
Additionally, the development of programmed cell death
and biochemical parameters in blood serum were studied at
4th day after infarction. Furnidipines’ metabolites effec-
tively reduced mortality index while did not markedly
influence on blood pressures parameters, arrhythmias, ST-
segment changes as well as biochemical parameters.
Intriguingly, programmed cell death study (TUNEL)
showed distinct increase in the amount of apoptotic nuclei
in post-infarcted myocardium, granulation tissue and what
is more in arteriolar walls after M-2 and M-3 application.
Moreover, M-2 turned out to be more powerful in stimu-
lation of apoptosis in granulation tissue surrounding
infarcted area whereas M-3 presented balanced profile in
this matter. Taking into account that programmed cell
death plays positive role in post-infarcted heart healing,
M-2 presents itself as more attractive agent for oral pre-
treatment in early stages of ischemia by non-stable indi-
viduals due to its more specific action in stimulation
repairing processes in granulation tissue as well as in
arteriolar walls. While M-2 and M-3 are common
metabolites present in degradation pathways of many
widely used dihydropyridines in clinic, this key fact put the
new outlook on understanding additional mechanism and
effects of not only furnidipines’ metabolites but also other
dihydropyridines.
Keywords Furnidipines’ metabolites  Reperfused
myocardial infarction  Programmed cell death  Rat 
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Introduction
Although reperfusion of the myocardium following coro-
nary occlusion reduces infarct size and improves its func-
tion [1, 2], numerous studies point to potential detrimental
effect of reperfusion on endothelium, myocardial muscle
structure, coronary vascular reactivity and potentially
lethal rhythm disturbances [3–5] as well as for apoptosis [6,
7]. In addition, observations made during therapeutic
revascularization procedures in infarct patients strongly
suggest that reperfusion might facilitate remobilization of
small vessels [8–10]. Despite considerable efforts, results
in protection or therapeutic management of reperfusion-
triggered pathologies and ischemic coronary artery dis-
eases still are far from being satisfactory.
The dihydropyridine derivatives (DHPs) currently used
for therapeutic purposes possess L-type calcium channel
blocking properties, and treatment of hypertension and
certain specific forms of angina pectoris remain to be their
main therapeutic indications [11]. In addition, it has been
shown that DHPs can protect the heart from stunning,
ischemia as well as ventricular arrhythmias, and that they
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possess beneficial effects against experimental atheroscle-
rosis [9, 10, 12–19]. Furthermore, many studies revealed
that calcium channel blockers can reduce infarct size in
experimental animals [5, 20–22]. It is unclear though,
whether these therapeutically interesting pharmacological
properties demonstrated for many DHPs are only due to
their blocking effects on the L-type calcium channel. In
fact, it is well established that some of them can enhance
opening probability of L-type channels [23] and yet others
can effectively modulate various ion channels and phar-
macological targets as well. Due to their different activi-
ties, DHPs are sometimes referred to be pharmacologically
‘‘privileged structures’’ [24, 25].
Attempts to reach such goals have led to the identifi-
cation of furnidipine (FUR) [26, 27]. Initially, FUR (for
structure see Fig. 1) was identified structurally and func-
tionally as a DHP with potent L-type calcium channel
blocking activity, good oral bio-availability and excep-
tionally high safety margin in pre-clinical studies [28, 29].
Later efforts to define its pharmacological activity profile
revealed though, that unlike most therapeutically used
calcium antagonists, FUR is highly selective in relaxing
both venous capacitance and arterial vessels resistance.
Although it has no influence on heart conduction system, it
revealed antiarrhythmic activity in the aconitine-induced
arrhythmias model in rats [26, 27, 29]. In addition, FUR
pretreatment afforded protection against norepinephrine-
induced cardiomyocyte necrosis in rats and its effective
dose range in this model was much broader than that of
nitrendipine. What is more, after oral as well as intravenous
pretreatment, FUR can not only dose-dependently influ-
ence on arterial blood pressure through the vessels relax-
ation and reduction in myocardial oxygen consumption, but
also can afford protection against reperfusion-triggered
myocardial damages and especially rats’ mortality decrease
evoked by lethal arrhythmias [30]. Interestingly, its pro-
tective effects on myocardial tissue damage, judged by the
creatine kinase reduction in blood, were observed as well
[30]. Although antihypertensive effects of FUR were
apparent in several animal models [26, 31] results of var-
ious controlled clinical trials indicated that in comparison
to several other calcium antagonists, its antihypertensive
efficacy is negligible.
At least two FUR metabolites lacking calcium channel
blocking activity with prolonged plasma half-life have
already been identified in human volunteers and called as
M-2 and M-3 [31]. In addition, plasma levels of FUR
oxidative metabolites were always higher than that of the
parent molecule after oral administration. Consequently,
both metabolites were screened for their typical blocking
activity and cardio-protective potential in several in vitro
models commonly used for such purposes [31]. Early data
in our laboratories have revealed similar efficacy of M-2 in
the same experimental model as used for FUR. Unlike
furnidipine, M-2 did not modulate blood pressure param-
eters or heart rate [30]. Furthermore, other authors proved
that M-2 itself did not influence significantly the guinea pig
cardiomyocyte action potential. However, it antagonized
dose-dependently (1 9 10-7–3 9 10-7 M) and markedly
the veratridine-induced action potential lengthening as well
as the anoxia-induced action potential shortening and
additionally, prevented from the cellular shape changes
[31].
Comparing the influence of continuous infusion of pro-
drug to M-2 and M-3 in working rats’ heart model [32–34].
We established that FUR evoked significantly weaker
influence on coronary and aortic flow, whereas both
metabolites caused a significant coronary flow increase.
What is more, M-3 caused the aortic systolic and diastolic
pressures decrease. Due to clear differences found between
all three agents, we concluded that the cardio-depressant
potency of both metabolites is overcome by advantageous
vasodilatatory effect. In addition, studying the effects of
Fig. 1 Structure of parent drug, furnidipine, and its metabolites M-2
and M-3
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M-2 in two different models of working heart ischemia
(low-flow and regional), we confirmed that it improved
coronary flow in both models, while favorably maintaining
aortic pressure parameters [35]. Moreover, it provided
outstanding protection against deleterious effects of cal-
cium overload (induced by veratridine in the Langendorff
heart) by significant prevention of the left ventricular
diastolic pressure rise and coronary flow decrease [36, 37].
Concluding these results, it allowed us to propose the
working hypothesis that the protective effects against cel-
lular damage evoked by FUR could be mainly attributed to
its metabolites and moreover, indicate other sites of action
different from the L-type calcium channel suggesting
pleiotropic effects on the ischemic heart by imparting
protection in various ways [34, 35, 38].
Since in vitro results do not always correspond to in vivo
outcomes, we studied the influence of M-2 on hemody-
namic parameters and ischemia- and reperfusion-induced
arrhythmias in rats [15, 30, 39] for further testing its
potential value as a therapeutic agent in infarcted hearts.
Dose- and time-response curves were obtained after oral
administration of M-2 in order to establish its pharma-
cokinetic properties and pharmacodynamic half-life. We
proved that it significantly reduced mortality, incidence
and duration of severe arrhythmias with differential influ-
ence on blood pressure, which depended on dose and time
of administration [35]. The optimal oral dose of M-2 and
M-3 was 20 mg kg-1 and those has been used in current
study as well.
Considering the all promising results, we decided to
perform present study in order to compare the effects of
M-2 as well as M-3 pretreatment on different forms of
arrhythmias, blood pressures and ST-segment changes
during occlusion (for 90 min) and reperfusion in the model
of myocardial infarction in rats evoked by permanent left
anterior descending coronary artery (LAD) occlusion [40].
Furthermore, the development of programmed cells death
and biochemical parameters in blood serum for the heart
damage were studied at 4th day after myocardial infarction.
Materials and methods
Experimental animals
Male Sprague–Dawley rats (n = 54; Central Animal Farm,
Medical University of Silesia, Katowice, Poland) weight-
ing approx. 320 ± 25 g and maintained under standard
condition (ambient temperature 21–23 C; with 12 h
dark/light cycle) with ad libitum access to food (Altromin
1220, Altromin GmbH, Lage, Germany) and tap water,
served as experimental animals. The animals were fasted
overnight before the experiment. The study was performed
with the approval of the Local Bioethical Committee and
all experiments were conducted in accordance with NIH
regulations of animals care described in the ‘‘Guide for the
Care and Use of Laboratory Animals’’ (NIH publication,
p. 2–107, revised 1996).
Drugs and reagents used
Two metabolites of furnidipine were used: M-2 [2,6-
dimethyl-5methoxy-carbonyl-4-(20-nitrophenyl)-pyridine-
3-carboxyliquide acid, MW 330.29] and M-3 [3-methyl
5-(tetrahydrofuran-2-yl) methyl 2,6-dimethyl-4-(20-nitro-
phenyl) pyridine-3,5-dicarboxylate, MW 414.45] (Fig. 1).
Both metabolites were supplied by Cermol S.A. (Geneva,
Switzerland) and were primarily dissolved in diluted
dimethylsulfoxide (DMSO) and later in water. For oral
administration, M-2 or M-3 solutions were prepared in
0.4 % aqueous dimethylsulfoxide and given in a volume of
5 mL kg-1 through inserted stomach-tube. Water was used
in the control group, nevertheless, in order to consider the
influence of DMSO itself, additional control group was
added (0.4 % DMSO). Unless otherwise stated, all other
reagents were of the highest purity and were supplied by
Sigma Chemical Co. (Deisenhofen, Germany).
Experimental infarction in rats
For this study an improved preparation previously descri-
bed by others [41, 42] with own modifications described in
details elsewhere [32, 40, 43–46] was used. The Lambeth
Conventions were used also as a guideline for this research
[47].
The rats were anesthetized with pentobarbital
(60 mg kg-1/at the beginning/?30 mg kg-1 i.p./10 min
before reperfusion/pentobarbital sodium salt Sigma,
Deisenhofen, Germany). To compare the depth of anes-
thesia, reflex response to noise and pain induced by the
pinching of the limbs and distal portion of the tail, were
tested in each rat at the beginning and the end of the
experiment as prescribed [48, 49]. Rectal temperature was
maintained at approximately 38 C.
The left common carotid artery was cannulated with a
filled catheter (saline with 2 IU mL-1 heparin) for systolic
and diastolic blood pressures (BPs, BPd) measurement
using a ISOTEC transducer (Hugo Sachs Elektronik,
March-Hugstetten, Germany).
The myocardial infarction was induced by permanent
left anterior descending coronary artery occlusion for
90 min and followed by 15 min of reperfusion. Only rats
that survived until 4 day after infarction were taken into
account during our investigations.
In brief, the trachea was incised longitudinally and
cannulated to allow artificial ventilation. The chest was
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opened under ventilation with room air (55–60 % humid-
ity, 23 C, stroke volume 0.8 mL 100 g-1 of body weight;
rate 54 strokes min with the positive end-respiratory
pressure of 1 cm H2O; Rodent VENTILATOR-UB 7025,
Hugo Sachs Elektronik, March-Hugstetten, Germany) [50]
by left thoracotomy at the fifth intercostal space and the
fifth and fourth ribs were sectioned approximately 2 mm
from the left margin of the sternum. After opening the
pericardium the heart was not exteriorized and a sling (6/0
Prolene 0.7 suture attached to 3/8 circled BV-1 a 9.3 mm
atraumatic, reverse cutting needle, EH 7406H, Ethicon
GmbH, Norderstedt, Germany) was placed around LAD
close to its origin (2 mm below). Then the ligature was
passed through a plastic pad (polyethylene, 2 mm OD/0.5
ID, thickness 0.2 mm). The left coronary artery was
occluded by applying tension to the ligature while pressing
the pad onto the heart surface. Tension was maintained by
clamping a climb clip (Titan climb clip, LT-100, Ethicon).
Successful occlusion was immediately confirmed by
ischemia-induced alteration in ECG (ST-elevation e.g.) and
observation of an arising pale ischemic zone below the
climb clip.
The ECG was picked up from standard limb leads using
needle electrodes and recorded synchronously with blood
pressure curve on high-speed chart recorders (ECG thermo
recorder E-30, Farum, Poznan´, Poland; 100 mm s-1 and
Line Recorder TZ 4620, Laboratorni Pristroje, Praha,
Czech, respectively) and displayed parallely on a digital
cardiomonitor (CMK 405, TEMED, Zabrze, Poland)
throughout the experiment.
Independently, all received signals (BP and ECG) were
transmitted through 16-channel A/D converter and stored
away by IBM compatible computer with the necessary own
software for data acquisition and elaboration (off-line).
At the end of the experiment (105 min), tissues were
sutured in layers (4-0 Deklene TM-II, 1.5, D-5427, Ethi-
con) excluding pericardium (avoiding heart tamponage).
The rats awaked in few hours after closing the thorax.
Furthermore, the rats which survived with myocardial
infarction were housed for next 4 days.
After this 4 days the rats were again anaesthetized with
pentobarbital (60 mg kg-1, i.p.). In the external jugular
vein, a PE 50 catheter was placed i.v. for the injection of
the Evan’s blue dye (to confirm successful reperfusion)
followed by pentobarbital for lethal anesthesia at the end of
the experiment.
The trachea was cannulated to allow artificial ventilation
with room air (Rodent VENTILATOR-UB 7025, stroke
volume 0.8 mL 100 g-1 body weight and rate 54 strokes
min-1, Hugo Sachs Elektronik, March-Hugstetten, Ger-
many). The chest was opened by a left thoracotomy, the
rats’ blood from aortic arch was collected for further
biochemical estimations and the heart was subsequently
excised in order to determinate myocardial infarct size as
well as saved in formalin (less than 7 days) for the routine
histological study and apoptosis (TUNEL) procedure
described below.
Experimental groups, design and measured
parameters
The rats were randomly divided into four groups. Same
doses of M-2 and M-3 (20 mg kg-1 each) or the vehicles
(water or 0.4 % DMSO in the volume of 5 mL kg-1 each)
were orally administered 1 h before LAD occlusion. At the
beginning of our study, each experimental group consisted
of: water (n = 7), DMSO (n = 13), M-2 (n = 12) and M-3
(n = 12) rats. The LAD was occluded for 90 min and then
reopened for 15 min. The mortality index (MI) was cal-
culated for the rats that survived this period (Table 1).
The continuous blood pressure parameters (BPs and
BPd) measurements were performed and recorded every
10 min during the occlusion and reperfusion (from 5th to
105th min; see Table 1). The ST-segment changes (in mm)
were estimated every 5 min during the occlusion and
reperfusion periods (see Table 2).
The number of the premature ventricular beats (PVBs)
during occlusion and reperfusion was counted as well as
the incidence (in %) and duration (in seconds) of the
spontaneously reversible ventricular fibrillation (VF),
ventricular tachycardia (VT), salvos, bigeminy or trige-
miny that occurred during both periods were measured
from the continuous ECG recordings using own software
(off-line) (see Table 3). All rhythms’ disturbances in rats
were distinguished due to rules described in details else-
where [47, 51] (Fig. 2).
Biochemical estimation in blood serum
At the 4th day of experiment, 1 mL of rats’ blood was
collected directly from aortic arch and without heparinizing
dissolved in saline (1/1 vol/vol.) to analyze creatine kinase
(CK, U/L; wavelength 340 nm, Reagent-test, Gilford,
Ciba-Cornig, Cambridge, MA, USA) [52], glutamate-
pyruvate transaminase (GTP, U/L, 340 nm) and glutamate-
oxaloacetate transaminase activity (GOT, U/L, 340 nm) in
order to estimate heart muscle damage as well as the level
of glucose (mg dL-1, 340 nm), urea (mg dL-1, 530 nm),
bilirubin (mg dL-1), creatinine (mg dL-1, 340 nm) and a-
amylase (U/L, 578 nm) spectophotometrically (Specol 220,
VEB Carl Zeiss, Jena, Germany) [53] (Table 4). In order to
obtain the physiological values of biochemical parameters
mentioned above, the intact group (n = 10) was added to
the trial.
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Determination of myocardial infarct size
After 4 days of the experiment, the heart was removed and
perfused 5 min through the cannula inserted into aorta with
1 mL of Evans blue (2 %; perfusion pressure 135 cm
H2O). Then it was frozen at -20 C for 5–20 min, cut into
1.5-2.0 mm sagittal sections and immersed in 1 % solution
of 2,3,5-triphenyltetrazolium chloride (TTC, Sigma, Poole,
UK) in phosphate buffer (20 mM, pH 7.4) at 37 C for
5–15 min. The white area without Evans blue and TTC
was considered as infarcted necrotic myocardium, the blue
area- normal myocardium and the red area (stained by
TTC)- ischemic myocardium. The myocardium was dis-
sected according to its colors and weighed separately. The
percentage ratio of the weight of infarcted necrotic myo-
cardium to that of total ischemic myocardium (infarcted
necrotic myocardium and ischemic non-necrotic myo-
cardium) was calculated and designated as the infarct size
[54]. The area of infarct in all survived animals (n = 34)
was 54 ± 6.8 %. All treatments and measurements were
performed by an experimenter blind to the treatment group.
Morphologic examination
The infarct-related areas of the heart tissue were fixed in
neutral buffered formaldehyde adjusted to pH 7.4. After
routine processing through graded alcohols and xylene, the
tissue was embedded in paraffin. Thin paraffin sections of
infarct-related areas of each sectioned heart were stained
with hematoxylin–eosin and Masson’s trichrome stains for
light microscopic histological evaluation.
The next stage after deparaffinization and dehydration
was subjected to enzymatic digestion in humid chamber (a
Petri dish, 20 cm OD for 5 slides) at 37 C with proteinase
K (final concentration 20 lg/mL in 10 mM/L Tris–HCl
buffer; pH 7.4–8.0). Tissue slices were dropped with 50 lL
enzyme solution and incubated for 30 min. During the
incubation the tissues slices were covered with parafilm.
After incubation the parafilm leaves were removed and
the slides were washed twice dropping distilled water
2 9 5 min). Endogenous peroxidase were blocked in using
0.3 % H2O2 in methanol per 30 min in Coplin jar at the
room temperature. Then the slides were washed twice with
PBS (phosphate-buffered saline; 2 9 1 min in Coplin jar)
and after permeation with 0.1 % Triton X-100 solution in
0.1 % sodium citrate TUNEL incubation was conducted in
humid chamber at 37 C during 30 min accordingly to
description for TUNEL kit (No 1 684 817 for In situ Cell
Death Detection Kit, POD, Boehringer Ingelheim, Man-
nheim, Germany).
The sites with UTP binding were labelled using con-
verter POD (anti-fluorescein antibody conjugated with
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reaction were visualised with diaminobenzidine (DAB)
procedure. Cellular nuclei were counterstained with
hematoxylin and cytoplasm slightly with eosin. Finally the
sides were dehydrated and mounted in Canada balsam. The
control, positive slides were made from rat prostate at 3rd
day after castration.
The stain in the cells labelled by TUNEL technique was
visualised as dark brown precipitate (dark cells). These
cells were considered as the cells during the programmed
cell death (PCD) process.
After histological evaluation, the main striking or rep-
resentative areas from the tissue were captured with digital
camera and written as *.tif files using 24 bit color palette at
fixed magnification (1509 magnification) using POLY-
VAR (Reichert-Leica) light microscope.
The quantitative evaluation of TUNEL-positive cells













































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 2 Characteristic electrocardiogram tracings (recorded from I
limb lead with recorder speed 100 mm s-1): a normal tracing before
left anterior descending coronary artery (LAD) occlusion, b ventric-
ular extrasystoly (VE), c multiple premature ventricular beats (PVBs),
d bigeminy, e ventricular tachycardia (VT), f ventricular fibrillation
(VF), g ST-segment elevation during ischemia/observed after LAD
occlusion/, h ECG tracing during late reperfusion
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DAB stained nuclei to all nuclei in a region of interest at
1509magnification, separately for myocardial muscle and
for resorptive granulation tissue in the site of infarcts’ three
consecutive areas [55]. All doubtfully stained areas were
excluded from calculations and assessment.
Statistical analysis
Blood pressures parameters (BPs, BPd), the ST-segment
changes, all forms of arrhythmias as well as biochemical
parameters were measured only in the reperfusion surviv-
ing animals. Except for the mortality index, all other results
are expressed as mean ± standard deviation (SD). Because
the data were not normally distributed, for all comparisons
non-parametric Kruskal–Wallis ANOVA test was used
[56] with appropriate post hoc test. In order to estimate the
significance between mortality and incidence of different
forms of arrhythmias, the Chi square-test (v2; Yates) was
used in all comparisons.
The quantitative evaluation of TUNEL-positive cells
were compared using Kruskal–Wallis test for equal medi-
ans and non-parametric ANOVA with Mann–Whitney
pairwise test as post hoc verification of significant proba-
bility (Statistica v. 10 software). In all cases differences
were considered significant at p\ 0.05.
Results
Mortality index, blood pressures parameters
and ECG study in occlusion and reperfusion
The mortality index did not differ significantly among
studied groups, however, in M-2 or M-3 treated animals
only two animals did not survive the experiment (16 %)
while in each controls groups three rats died (42.8 and
23.1 %, respectively) (Table 1).
During 105 min of the continuous blood pressure mea-
surement no significant changes were considered in
occlusion as well as in reperfusion between studied groups
(Table 1). Similarly, no significant changes have been
found in ST-segment between studied groups (Table 2).
Unlikely, the number of PVBs was significantly reduced
in reperfusion in compare to occlusion period in all groups
(p\ 0.05). In addition, the bigeminy duration in reperfu-
sion was markedly reduced after M-2 pretreatment
(p\ 0.05). Similar action was observed concerning the
trigeminy duration, but this effect was not significant
(Table 3).
Biochemical estimation in serum samples
A single administration of water, 0.4 % DMSO, M-2 or
M-3 did not significantly influence on the concentration of
glucose, amylase, urea and GTP measured in blood serum
at 4th day after infarction.
Only M-3 single pretreatment reduced significantly
glutamate- oxaloacetate transaminase concentration in
comparison to water control group (p\ 0.05), however,
M-2 and DMSO groups slightly diminished this parameters
as well (Table 4). Similarly, M-3 strongly reduced creatine
kinase concentration in comparison to M-2 and DMSO
groups (p\ 0.05). It should be mentioned that M-2 caused
the highest increase of this parameter among all tested
groups. The concentrations of bilirubin and creatinine in
serum were below the detection limit in all groups
(Table 4).
Table 4 Effects of single oral pretreatment with 20 mg kg-1 of M-2 or M-3 on blood parameters measured after 90 min of left anterior coronary
occlusion and 15 min of reperfusion in rats
Experimental
group







Amylase (U/L) GTP (U/L) GOT (U/L) Creatine kinase
(U/L)
Urea (mg/Dl)
Intact n = 10 139.6 ± 6.92 \0.5 \0.5 4 323.3 ± 241.9 21.35 ± 1.29 109.8 ± 9.3 216.4 ± 87.7 53.46 ± 2.68
Control
n = 4/7
137 ± 31.7 \0.5 \0.5 2 975 ± 697.6 24.8 ± 3.86 109.6 ± 10.3* 384.2 ± 106.8 59.5 ± 0.7
DMSO
n = 10/13
137.9 ± 17.6 \0.5 \0.5 2 996 ± 512 23.1 ± 5.86 84.8 ± 13.5 362.7 ± 105.2* 60.3 ± 6.7
M-2 n = 10/
12
128.3 ± 20.2 \0.5 \0.5 3 169 ± 1063.8 22 ± 6.53 85.5 ± 24.8 481.2 ± 317.5* 54.6 ± 7.03
M-3 n = 10/
12
139.1 ± 12 \.5 \0.5 2 779 ± 627.4 20.2 ± 4.8 64.1 ± 18 184.7 ± 88 60 ± 3.82
Bilirubin and creatinine were below detection limit. For other details see Table 1 and text. The differences in blood parameters was calculated
using non-parametric Kruskal–Wallis ANOVA test with appropriate post hoc test
Values marked with * p\ 0.05 are significantly different from the values of M-3 group
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Morphological study
At 4th day after myocardial infarction, the histological
findings in all studied slices were generally similar in
treated and non-treated rats. They represented resorptive
inflammatory infiltrations inside and granulation tissue
(data not shown).
Programmed cell death
At 4th day after myocardial infarction, TUNEL-positive
cell nuclei were present scanty in control and DMSO
groups in myocardial cells as well as in granulation tissue,
whereas in M-2 and M-3 groups brownish stained TUNEL-
positive nuclei were easily recognized in both lesions
(Figs. 3, 4). Moreover, in M-2 and M-3 treated animals,
apoptotic cells were found also in arteriolar walls, whereas
in control and DMSO groups this phenomenon was never
exhibited (Fig. 5). Statistical analysis revealed marked
increase in the amount of apoptotic nuclei after both
furnidipines’ metabolites treatment in myocardial as well
as granulation tissue, when compared to control and
DMSO groups. Additionally, M-3 presented significantly
stronger proapoptotic effect than M-2 in all cases. The
statistical and quantitative results are presented in details in
Figs. 3 and 4.
Discussion
In chosen rats’ model of myocardial infarction followed by
15 min of reperfusion, the single oral pretreatment with
both studied metabolites effectively reduced mortality
index of the animals, did not markedly influence on blood
pressure as well as on the ST-segment changes (Table 1,
2). Whereas the number of premature ventricular beats was
significantly reduced in reperfusion in comparison to
occlusion, this was found in all groups. Hence it could not
be described as an effect of any of furnidpines’
metabolites.
It can be generally assumed that the all kinds of
arrhythmias occurred in occlusion were strongly reduced in
reperfusion. It is mainly due to the fact of enough long
occlusion in this model, but not to the influence of tested
agents. Nevertheless, it has been shown that the same dose
of M-2 significantly reduced mortality as well as the ven-
tricular fibrillation incidence and duration in reperfusion,
but after just 7 min of LAD occlusion in the model of
ischemia- and reperfusion arrhythmias in rats [35]. The
biochemical findings in blood at 4th day after myocardial
infarction showed that only the M-3 pretreatment reduced
significantly GOT concentration in comparison to control
as well as it strongly reduced CK values in comparison to
M-2 and DMSO groups (p\ 0.05). Although some bene-
ficial effects of the tested compounds were present, in view
of our previous experiments with these agents [34, 35, 38,
57] it could be concluded that the model used in present
study is not suitable to quantify their optimal cardiopro-
tective effects.
Despite the fact that no visible differences were found in
routine histopathological investigation, the most intriguing
results of this research concern the programmed cell death
study. At 4th day after reperfused infarcted rats’ heart,
TUNEL-positive cell nuclei were present scanty in
myocardial cells as well as in granulation tissue in control
and DMSO groups, whereas in M-2 and M-3 groups
brownish stained TUNEL-positive nuclei were easily rec-
ognized in both tissues. At least in this issue, the clear
difference between M-3 and M-2 due to proapoptotic
influence was found. In both tissues, the M-3 increased
approx. 30 % the number of TUNEL-positive nuclei, while
the M-2—approx. 5 %. Moreover, several differences in
apoptotic rate between ischemic myocardium and granu-
lation tissue were noticed after application of each agent.
Percentage of the total effect in both tissues (calculated as
in the example of DMSO granulation: 5/negative/?3/pos-
itive/ = 8, what results 3/positive/is 37 % of total)
revealed that: (a) DMSO stimulated apoptosis in granula-
tion tissue only (37 %), (b) M-2 is more powerful in
apoptosis stimulation in granulation tissue than in post-
ischemic myocardium cells (52 vs 32 %), (c) M-3 is
equally potent in apoptosis stimulation in both tissues
(approx. 50 %).
According to these results, M-2 is more likely in pro-
moting apoptosis in granulation tissue, while M-3 possess
more balanced profile for apoptosis stimulation in both
tissues.
It should be also noticed that we cannot exclude the
DMSO membrane effects on apoptosis stimulation in
granulation tissue caused by both furnidipines’ metabolites.
The obligatory use of DMSO as a solvent for dihydropy-
ridines derivatives (even in the concentrations lower than
0.4 %) will always mimics to some extend these agents’
action due to its ability to generate apoptosis per se [58,
59].
Interestingly, apoptotic cells were also found in arteri-
olar walls after both metabolites administration, whereas in
control and DMSO groups this phenomenon was not
observed at whole.
In view of the fact presented above, the fundamental,
controversial questions return: whether the apoptosis in
general is beneficial for healing, remodeling processes after
myocardial infarction and whether the proapoptotic or
antiapoptotic agents are wanted participants in this game?
Although programmed cell death proceeds by the same
mechanism in each cell, the meaning of this process in
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heart healing can be different, due to the consequences it
brings. Whereas ongoing process of apoptosis may be
beneficial in one condition, in other it may be linked with
detrimental effects. It appears obvious that apoptosis con-
tributed with myocyte loss as well as organising fibrotic
tissue in the place of ischemia results in sustained con-
tractile failure of myocardium [60]. Other authors reported
also that myocytes apoptosis is likely to precede necrosis
connected with disintegration of cells and in consequence,
deterioration of heart function [61, 62]. Furthermore, the
experimental study on mice proved that inhibition of
apoptotic cascade by transfer of adenoviral antiapoptopic
soluble Fas gene in the 3rd day after ligation-induced
myocardium infarction could be potentially valuable
therapeutic strategy in cardiac diseases [63]. In addition,
recent data revealed as well that anoikis, defined as special
type of PCD induced by cell detachment, is responsible for
pathological remodeling of cardiovascular tissue in heart
failure [64, 65].
On the other hand, the functional role of apoptosis in
granulation tissue seems to have different meaning.
According to the fact that TUNEL detection of apoptosis is
not limited to the dying myocytes, but it also points out
other cells undergoing this process [62], TUNEL positivity
in granulation tissue may be related to the presence of
inflammatory cells which accumulate in the injured myo-
cardium area. It is well established the infiltrated leuco-
cytes and macrophages play essential role in infarct healing
Fig. 3 Representative images
of apoptotic staining and their
quantificative results in rats’
myocardial tissue after single
oral pretreatment with
20 mg kg-1 of M-2 or M-3.
a TUNEL reaction. Control
(upper left): Only one slightly
stained brownish cardiocytic













10 lm). M-2 (down left):
TUNEL-positive cardiocytic





10 lm). M-3 (down right):
TUNEL-positive cardiocytic





10 lm). b. Percentage of
TUNEL-positive nuclei per total
nuclear area
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by their ability of scavenging ischemic area from death
myocytes as well as stimulation of angiogenesis and
myofibroblast proliferation [66]. In addition, the inflam-
matory cells after fulfilling their role undergo the process
of PCD which is, in comparison to necrosis, a ‘safe death
pathway’ which protects survived myocytes from excessive
inflammation process caused by release of their cytotoxic
factors such as cytokines and proteases [62].
Moreover, our finding of apoptotic cells in arteriolar
walls in M-2 and M-3 treated groups sounds favourably in
the light of the statement indicating that apoptosis helps in
rebuilding the intima of coronary vasculatures by elimi-
nation of injured cells, what results in quicker growth of
new endothelium [62].
In general, the balance between programmed cell death
and regeneration processes in all kinds of tissues seems to
be crucial aspect in determination of myocardium recovery
after infarction. In the light of the histological results
presented above, M-2 shows itself as more attractive agent
for oral pretreatment in early stages of ischemia by non-
stable individuals suggested elsewhere [57] due to its more
specific action in stimulation resorptive processes in
granulation tissue as well as in arteriolar walls. Further-
more, this working hypothesis enlarge our outcomes from
previous study where M-2 positively influenced on post-
infarction heart remodeling. We have proved, M-2
administration from 6th to 35th day after infarction effec-
tively prevents cardiomyopathy development through the
Fig. 4 Representative images
of apoptotic staining and their
quantificative results in rats’
postischemic granulation tissue
after single oral pretreatment
with 20 mg kg-1 of M-2 or
M-3. a TUNEL reaction.
Control (upper left): All visible
cells, including inflammatory






10 lm). DMSO (upper right):
Only few positively stained
brown nuclei (TUNEL-positive)






10 lm). M-2 (down left):
TUNEL-positive endothelial
cell nuclei and inflammatory





10 lm). M-3 (down right):
Numerous TUNEL-positive
inflammatory and fibroblastic





10 lm). b Percentage of
TUNEL-positive nuclei per total
nuclear area
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revitalisation of the coronary arteries, infarct scar remod-
eling as well as acceleration of angiogenic events [38].
Although apoptosis can be induced by ischemia itself
[62], it cannot succeed without oxygen as it is active,
energy- requiring process. Accordingly, reperfusion is one
of the triggers responsible for promoting the apoptotic
cascade and is associated with higher TUNEL positivity
[62, 67]. It has been proven the apoptotic nuclei are par-
ticularly evident in the infarcted areas where spontaneous
reperfusion most often occurs [61, 68]. The higher amount
of TUNEL-positive nuclei in samples collected from M-2
and M-3 groups suggests better reperfusion in myocardium
cells in groups pretreated with furnidipines’ metabolites in
contrast to control and DMSO groups. Clearly, this effect
may be achieved due to their proven various vasodilatatory
effect as well as increase in cardiac coronary flow [34].
In order to explain relationship between histological
outcomes of presented study evoked by furnidipines’
metabolites we should also take a closer look at the
molecular mechanism of apoptosis and M-2 actions in
general. It is well known that myocardial ischemia–reper-
fusion is associated with elevated content of intracellular
Ca2? (especially in mitochondria), which is also a major
trigger of the apoptotic intrinsic pathway [69]. Due to the
fact all dihydropyridines are proved to possess the ability
of L-type calcium (Ca) channel blocking, they seem to be
potential pharmacological protectors of the damaging
caused by pro-apoptotic intracellular Ca2? overload. Since
many contradictory opinions were presented on this issue,
their role in this application still remains controversial.
Some authors claim that these group of drugs cannot be
effective in apoptosis inhibition while they do not influence
on the sodium-hydrogen exchanger (NHE) which is indi-
cated to be major Ca2? transporter in the process of cell
death [62, 69]. It has been suggested M-2 acts as a sodium
and outward potassium ATP-dependent channels gating
protector, while it effectively reduced ([90 %) anoxia-in-
duced action potential shortening and veratridine-induced
action potential lengthening [35]. Despite of the lack of its
cardio-depressive action [34] which could be linked with
the M-2 poor activity on calcium channels, some experi-
ments have revealed decrease of the intracellular free cal-
cium ion concentration during hypoxia in non-stimulated
isolated guinea pig cardiomyocytes after M-2 administra-
tion. This could be due to an effect on an alternative cal-
cium entry via modified sodium channels or via
sodium/calcium ions exchange [31]. It is worth stressing
that besides its wide spread activity, M-2 as a potential NO
donor is supposed to decrease intracellular Ca concentra-
tion through cyclic GMP-dependent mechanism [38, 62].
Nevertheless, it should be remembered that the crosstalk
between mechanism of apoptosis and M-2 action is sug-
gestive and needs further elucidation.
In conclusion, searching for confirmation of results
obtained in our previous studies concerning favourable
effects of furnidipines’ metabolites (especially M-2)
administration on mortality, blood pressure, arrhythmias
and post-infarcted remodeling, one could consider that our
expectations for next beneficial outcomes to some extent
failed. Despite there are no distinguishing differences
regarding FUR metabolites hemodynamic profiles as well
as arrhythmias incidence and duration, fortunately, we
decided to challenge the problem at the histopatological
level as well. Surprising effect of M-2 and M-3 single
pretreatment paired with higher apoptotic rate in post-is-
chemic myocardium as well as in granulation tissue and
what is more, in arteriolar walls is a major interest and
again makes furnidipines’ metabolites intriguing objects
for future investigations.
It must be remembered, M-2 and M-3 are common
metabolites present in degradation pathways of many and
widely used dihydropyridines in clinic, especially in long-
term secondary prevention of myocardial infarct.
This key fact put the new outlook on understanding
additional mechanism and effects of not only furnidipines’
metabolites as well as other dihydropyridines.
Taking into account, that programmed cell death could
play positive role in post-infarcted heart healing, it might
be summarized: M-2 is more specific in stimulation of
repairing processes in granulation tissue after occlusion-
induced myocardium infarction. Accordingly, it may allow
to introduce a novel class of agents with attractive prop-
erties, which do not belong to dihydropyridines derivatives
due to their different chemical structure.
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